



**Protocol for a prospective neuro-imaging study
investigating the supraspinal control of lower urinary tract
function in healthy controls and patients with and without
lower urinary tract symptoms**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004357
Article Type:	Protocol
Date Submitted by the Author:	29-Oct-2013
Complete List of Authors:	Walter, Matthias; Spinal Cord Injury Center & Research, University of Zurich, Neuro-Urology Michels, Lars; University Hospital Zurich, Institute of Neuroradiology Kollias, Spyros; University Hospital Zurich, Institute of Neuroradiology van Kerrebroeck, Philip; University Hospital Maastricht, Department of Urology Kessler, Thomas; Spinal Cord Injury Center & Research, University of Zurich, Neuro-Urology Mehnert, Ulrich; Spinal Cord Injury Center & Research, University of Zurich, Neuro-Urology
Primary Subject Heading:	Urology
Secondary Subject Heading:	Radiology and imaging
Keywords:	Neuro-urology < UROLOGY, Bladder disorders < UROLOGY, Urinary incontinences < UROLOGY, Neuroradiology < RADIOLOGY & IMAGING, Multiple sclerosis < NEUROLOGY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Protocol for a prospective neuro-imaging study investigating the supraspinal control of lower urinary tract function in healthy controls and patients with and without lower urinary tract symptoms

Matthias Walter¹, Lars Michels², Spyros Kollias², Philip E. van Kerrebroeck³, Thomas M. Kessler¹, Ulrich Mehnert^{1,#}

Corresponding author

For peer review only

ABSTRACT

Introduction: Lower urinary tract symptoms (LUTS) are highly prevalent, cause an enormous economic burden on health care systems, and significantly impair quality of life (QoL) of affected patients. The dependence of the lower urinary tract (LUT) on complex central neuronal circuits makes it unique in comparison to other visceral functions, such as the gastrointestinal tract, but also more vulnerable to neurological diseases.

Methods & analysis: This is a prospective neuro-imaging study investigating the supraspinal control of LUT function in healthy controls and patients with and without LUTS. The clinical assessment will include medical history, neuro-urological examination, bladder diary, urine analysis, urodynamic investigations, as well as standardized questionnaires regarding LUTS and QoL.

The acquisition of neuro-imaging data will include structural assessments with diffusion tensor imaging (DTI) and voxel-based morphometry (VBM) as well as functional investigations using blood-oxygen-level-dependent (BOLD) sensitive functional magnetic resonance imaging (fMRI) in a 3T magnetic resonance (MR) scanner. The fMRI will be performed during four different bladder tasks. The first three tasks will consist of automated, repetitive filling of 100mL warm (37°C) saline starting with (1) an empty bladder, (2) a low prefilled bladder volume (100mL), and (3) a high prefilled bladder volume (until a persistent desire to void). The fourth task will comprise of automated, repetitive filling of 100mL cold (4-8°C) saline starting with an empty bladder.

Ethics & dissemination:

The local ethics committee approved this study (KEK-ZH-Nr. 2011-0346). The findings of the study will be published in peer-reviewed journals and presented at national and international scientific meetings.

Trial registration:

This study has been registered at [clinicaltrials.gov](http://www.clinicaltrials.gov) (<http://www.clinicaltrials.gov/ct2/show/NCT01768910>).

ARTICLE SUMMARY

Study focus

- To demonstrate correlations between alterations in brain structural and functional connectivity in relation to LUT control and LUTS, i.e. urgency with or without urgency urinary incontinence, and urinary frequency.
- To compare clinical correlates of treatment responses in patients receiving treatment for LUTS with the associated changes in brain activity and connectivity.

Key messages

- Although recent neuro-imaging studies in humans and neuro-physiological animal studies have contributed to establish concepts of spinal and supraspinal LUT control, the exact pathophysiological mechanisms involved in human LUTS are still largely unknown.
- Multimodal neuro-imaging approach has considerable potential to broaden our knowledge of the supraspinal LUT control in contrast to the current concepts.

Strengths and limitations of this study

- This will be the first study to correlate findings from structural and functional MRI techniques with clinical measurements to identify abnormalities in brain networks responsible for the supraspinal control of LUT function in healthy controls and patients with and without LUTS.
- Correlations revealed by analysing neuro-imaging data in regard to the clinical context will establish functional biomarkers in patients with and without LUTS.

INTRODUCTION

Lower urinary tract symptoms (LUTS) are highly prevalent, i.e. about 11% in the worldwide population in 2008, and forecasted to increase up to 20% until 2018.^{1 2} Moreover, LUTS cause an enormous economic burden on each health care systems,^{3 4} i.e. comparable to diabetes mellitus,⁵ and significantly impair the quality of life (QoL) of affected patients.^{6 7}

For a proper functioning, lower urinary tract (LUT) structures, i.e. bladder, bladder neck, urethra, and urethral sphincter, rely on intact neuronal innervations that are under control of a complex supraspinal network.⁸⁻¹⁰ The dependence of the LUT on such complex central neuronal circuits makes it unique in comparison to other visceral functions, e.g. gastrointestinal tract, but also more vulnerable to neurological diseases.¹⁰

Recent neuro-imaging studies have shown that patients with neurological disorders such as Parkinson's disease (PD)¹¹⁻¹³ and spinal cord injury (SCI)¹⁴ demonstrate different supraspinal activity patterns compared to healthy controls in response to LUT stimulation tasks, which might represent a neural correlate to their LUTS.

Although there are several concepts regarding the human LUT function and neuronal control in normal and pathological conditions, the exact pathophysiological mechanisms involved remain largely unknown.⁹ As brain and brainstem are crucial for voluntary LUT control^{10 15 16}, investigation of the supraspinal regions with high-resolution imaging techniques, i.e. functional magnetic resonance imaging (fMRI), can significantly contribute to increase our understanding on the effects of supraspinal lesions and alterations related to LUTS.^{10 17}

In this study, we are aiming to identify supraspinal areas associated with LUT control in healthy controls and in patients with and without LUTS. Blood-oxygen-level-dependent (BOLD) fMRI, resting-state fMRI (RS-fMRI)¹⁸, voxel-based morphometry (VBM)¹⁹, diffusion tensor imaging (DTI)²⁰, functional connectivity (FC) analysis, and structural integrity evaluation of white matter tracts and gray matter concentration will enable us to identify specific alterations of the supraspinal LUT control to better understand the relevant components and dysfunctions of this network.

METHODS AND ANALYSIS

Study design

This prospective research study will be conducted at the University of Zürich, Zürich, Switzerland.

Study population & recruitment

According to the inclusion and exclusion criteria (Table 1), healthy controls with an unimpaired LUT function and patients with and without LUTS will be investigated.

Patients will be recruited from our own department (Neuro-Urology, Balgrist University Hospital, Zürich) and through our partners at the University Hospital Zürich and the Triemli Hospital Zürich. Eligible patients and healthy controls will be invited to a first visit (screening) during which detailed information about the study, in particular the aims, methods, possible risks, and side effects, will be given. After obtaining written informed consent, the following data will be collected: medical history, a 3-day bladder diary, urine sample to exclude urinary tract infection (UTI) and pregnancy in female subjects, urodynamic parameters, and post void residual measured by ultrasound as well as standardized questionnaires regarding LUTS and QoL. The validated German versions of these questionnaires will be used with permission of the International consultation on incontinence modular questionnaire [(ICIQ), Bristol Urological Institute, Southmead Hospital Bristol, UK], and will address the LUTS (ICIQ-LUTS) in both females (ICIQ-FLUTS) and males (ICIQ-MLUTS) whereas the ICIQ-LUTSQoL will display the QoL in regard to LUTS.

Determination of sample size

Considering our earlier studies^{14 21}, which provided statistical evidence using small collectives, i.e. 14 and 15 subjects respectively, we estimated the sample size for each group: healthy controls (20), multiple sclerosis (MS) patients with or without LUTS (each 15) and patients with LUTS, but without any underlying neurological disease (20). Other studies confirmed this sample size to enable statistically significant results.^{22 23}

Study location

- Neuro-Urology, Spinal Cord Injury Centre & Research, University of Zürich, Balgrist University Hospital, Zürich, Switzerland
- MR-Centre, University Hospital Zürich, Zürich, Switzerland

Partners

- NeuroRadiology Clinic, University Hospital Zürich, Zürich, Switzerland
- Departments of Urology, Neurology, and Gynaecology, University Hospital Zürich, Zürich, Switzerland
- Department of Urology and Gynaecology, Triemli Hospital, Zürich, Switzerland

Investigations

Following screening and study inclusion, all subjects will be scheduled for the 2nd and 3rd visits (1st and 2nd fMRI measurement) at the MR-Centre. Patients with LUTS might return for a 4th visit (3rd fMRI measurement) after receiving treatment for LUTS (Figure 1).

MR scanning will be performed using a Philips Ingenia 3.0 Tesla MR scanner (Philips Medical Systems, Best, The Netherlands) with an 8-element head coil. The scan will start with structural MRI including DTI, VBM, and then RS-fMRI. After placement of a transurethral catheter, RS-fMRI will be repeated. Subsequently BOLD fMRI will be acquired to investigate the supraspinal activity during four different bladder tasks (Figure 2). In the first three fMRI tasks, we will examine the effect of visceral bladder sensation by automated, repetitive filling with 100mL warm (37°C) saline starting with (1) an empty bladder, (2) a low prefilled bladder volume (100mL), and (3) a high prefilled bladder volume (until a persistent desire to void). The fourth task will consist of automated, repetitive filling of 100mL cold (4-8°C) saline starting with an empty bladder to investigate the neural correlates of cold bladder sensation (Figure 3). Subjects will rate their urge to void and also the level of pain using a displayed visual analogue scale (VAS) and an fMRI-compatible, multi-configurable handheld response system.²⁴

Safety

The staff involved in this study will be instructed and trained according to the safety regulations of the MR-Centre of the University Hospital Zürich. All subjects will be asked to remove any ferromagnetic items, e.g. bra, earrings, chains, rings, and piercings prior to entering the scanner room. All subjects will be provided with standardised clinical scrubs instead of wearing their own clothes. Before every MR-scan, urine samples will be analysed from every subject in order to exclude UTI or pregnancy. In case of pregnancy, the subject will be excluded from the study and referred to a gynaecologist. In case of UTI, the subject will not undergo the experiment, but will receive immediate antibiotic treatment if the UTI is symptomatic or treatment depending on further microbiological urine analysis in the absence of UTI symptoms. The subject can be reassigned to the study, if the microbiological urine analysis shows no evidence of an UTI or the UTI has been successfully treated.

1
2
3 In the situation of an adverse event (AE) or a severe adverse event (SAE), as defined by the
4 international conference on harmonisation (ICH) good clinical practice (GCP) guidelines
5 (E6)²⁵ and international organization for standardization (ISO, 14155)²⁶, appropriate actions
6 will be executed and the according body (principle investigator, ethics committee) will be
7 informed. All AEs and SAEs will be followed as long as medically indicated.
8
9

10 11 12 **Study outcome measures**

13 Primary

14 BOLD signal intensity changes in supraspinal regions of interest (ROI), e.g. pons, insula,
15 anterior cingulate cortex, thalamus, hypothalamus, supplementary motor area, and prefrontal
16 cortex, in relation to the according fMRI tasks during two (healthy controls and patients
17 without LUTS) or three (patients with LUTS) visits.
18
19
20
21

22 Secondary

23 To analyse structural (SC) and functional connectivity (FC) between supraspinal ROI and to
24 identify specific alterations, i.e. changes of BOLD signal (RS-fMRI), white matter fibre
25 structure (DTI), and gray matter concentration (VBM) data, in patients with LUTS compared
26 to healthy controls and patients without LUTS.
27
28

29 Furthermore, factors like age, bladder volume, urodynamic parameters and level of urge to
30 void during fMRI, will be used as regressors for statistical analysis of SC and FC.
31
32
33
34

35 **Data analysis**

36 Clinical data will be statistically analysed and compared between groups using IBM's
37 Statistical Package for the Social Sciences (SPSS) version 19.0 (Armonk, New York, U.S.).
38 Urodynamic parameters, urine volume measurement including post void residual
39 (ultrasound), and feedback rating will be presented with means and standard deviations or
40 with medians and interquartile ranges as appropriate. Association of individual (independent)
41 variables on the outcome variables will be reported using correlation coefficients. Results
42 from univariate analysis will inform multivariate modelling. Assessment of causal
43 associations will be performed using multivariate models including potential confounders
44 along with the independent variables of interest.
45
46
47
48
49

50 The neuro-imaging data will be analysed using statistical parametric mapping (SPM) version
51 8 (Wellcome Department of Imaging Neuroscience, University College London, UK) and
52 toolboxes (e.g. Diffusion II and VBMtools).
53
54
55
56
57
58
59
60

ETHICS AND DISSEMINATION

This cohort study will be performed in accordance to the World Medical Association Declaration of Helsinki²⁷ and the guidelines of the Swiss Academy of Medical Sciences.²⁸

This study has been approved by the local ethics committee (Kantonale Ethikkommission Zürich, KEK-ZH-Nr. 2011-0346). Furthermore, handling of all personal data will strictly comply with the federal law of data protection in Switzerland.²⁹

This study has been registered at [clinicaltrials.gov](http://www.clinicaltrials.gov) (<http://www.clinicaltrials.gov/ct2/show/NCT01768910>).

DISCUSSION

This study will investigate supraspinal LUT control in healthy subjects and patients with and without LUTS using a multimodal imaging protocol including fMRI, DTI, VBM, and FC analysis. In addition, effects on the supraspinal LUT control after treatment for LUTS will be investigated. It is expected that this study will provide new insights into the supraspinal neuronal mechanisms and networks responsible for LUT control. The findings will help to verify, amend, or adjust neuronal circuitry models established from findings in healthy subjects, now in the context of patients with or without LUTS. Particularly, the use of newer imaging and evaluation techniques like RS-fMRI, DTI, VBM, and FC analysis have the potential to serve as quantifiable biomarkers for therapy success and provide evidence for non-responders of LUTS treatment.

Author affiliations

1 Neuro-Urology, Spinal Cord Injury Centre & Research, University of Zürich, Balgrist University Hospital, Zürich, Switzerland

2 Institute of Neuro-Radiology, University of Zürich, University Hospital Zürich, Zürich, Switzerland

3 Department of Urology, University Hospital Maastricht, Maastricht, The Netherlands

Acknowledgements

We would like to acknowledge the Swiss National Science Foundation and SwissLife Jubiläumsstiftung for financial support. Furthermore, we would like to thank our partners contributing to this study: Departments of Urology, Neurology and Gynaecology of the University Hospital Zürich and Departments of Urology and Gynaecology, Triemli Hospital, Zürich, Switzerland.

We thank Behnaz Jarrahi for granting figure contents.

Contributors

All authors participated in creating the study design.

MW and UM drafted the manuscript.

LM, SK, PEVK and TMK critically reviewed the manuscript.

UM, SK and TMK obtained the funding of this study.

All the authors read and approved the final manuscript.

Funding

Swiss National Science Foundation (grant number: 135774)

SwissLife Jubiläumsstiftung

Competing interests

The authors declare that they have no competing interests.

REFERENCES

1. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-Based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. *European Urology* 2006;50(6):1306-15.
2. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. *BJU International* 2011;108(7):1132-38.
3. Ganz ML, Smalarz AM, Krupski TL, Anger JT, Hu JC, Wittrup-Jensen KU, et al. Economic costs of overactive bladder in the United States. *Urology* 2010;75(3):526-32.e18.
4. Klotz T, Brueggenjuergen B, Burkart M, Resch A. The economic costs of overactive bladder in Germany. *European Urology* 2007;51(6):1654-63.
5. Hampel C, Gillitzer R, Pahernik S, Hohenfellner M, Thüroff JW. Epidemiologie und Ätiologie der instabilen Blase. *Der Urologe, Ausgabe A* 2003;42(6):776-86.
6. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. *BJU International* 2008;101(11):1388-95.
7. Irwin DE, Milsom IAN, Kopp ZOE, Abrams P, Cardozo L. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. *BJU International* 2006;97(1):96-100.
8. Blok BF. Brain control of the lower urinary tract. *Scandinavian Journal of Urology and Nephrology Supplement* 2002;36(210):11-5.
9. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. *Nature Reviews Neuroscience* 2008;9(6):453-66.
10. Fowler CJ, Griffiths DJ. A decade of functional brain imaging applied to bladder control. *Neurourology and Urodynamics* 2010;29(1):49-55.
11. Kitta T, Kakizaki H, Furuno T, Moriya K, Tanaka H, Shiga T, et al. Brain activation during detrusor overactivity in patients with Parkinson's disease: a positron emission tomography study. *The Journal of urology* 2006;175(3 Pt 1):994-8.
12. Herzog J, Weiss PH, Assmus A, Wefer B, Seif C, Braun PM, et al. Subthalamic stimulation modulates cortical control of urinary bladder in Parkinson's disease. *Brain* 2006;129(Pt 12):3366-75.
13. Herzog J, Weiss PH, Assmus A, Wefer B, Seif C, Braun PM, et al. Improved sensory gating of urinary bladder afferents in Parkinson's disease following subthalamic stimulation. *Brain* 2008;131(1):132-45.
14. Mehnert U, Michels L, Zempleni M-Z, Schurch B, Kollias S. The supraspinal neural correlate of bladder cold sensation - an fMRI study. *Human Brain Mapping* 2011;32(6):835-45.
15. Andrew J, Nathan PW. Lesions of the anterior frontal lobes and disturbances of micturition and defaecation. *Brain* 1964;87(2):233-62.
16. Holstege G. Micturition and the soul. *The Journal of Comparative Neurology* 2005;493(1):15-20.
17. de Groat WC. A neurologic basis for the overactive bladder. *Urology* 1997;50(6, Supplement 1):36-52.
18. Biswal BB, Kylen JV, Hyde JS. Simultaneous assessment of flow and BOLD signals in resting-state functional connectivity maps. *NMR in Biomedicine* 1997;10(4-5):165-70.
19. Ashburner J, Friston KJ. Voxel-Based Morphometry - The Methods. *NeuroImage* 2000;11(6):805-21.
20. Basser PJ, Mattiello J, LeBihan D. MR diffusion tensor spectroscopy and imaging. *Biophysical journal* 1994;66(1):259-67.
21. Michels L, Mehnert U, Boy Sn, Schurch B, Kollias S. The somatosensory representation of the human clitoris: an fMRI study. *NeuroImage* 2010;49(1):177-84.

- 1
2
3 22. Griffiths D, Derbyshire S, Stenger A, Resnick N. Brain control of normal and overactive
4 bladder. *The Journal of urology* 2005;174(5):1862-67.
5 23. Griffiths D, Tadic SD, Schaefer W, Resnick NM. Cerebral control of the bladder in normal
6 and urge-incontinent women. *NeuroImage* 2007;37(1):1-7.
7 24. Jarrahi B, Wanek J, Mehnert U, Kollias S. An fmri-compatible multi-configurable
8 handheld response system using an intensity-modulated fiber-optic sensor. *35th*
9 *Annual International IEEE EMBS Conference*. Osaka, Japan, 2013.
10 25. International conference on harmonisation. Good clinical practice guideline, 1996.
11 26. International organization for standardization. ISO 14155, 2011.
12 27. World Medical Association. Declaration of Helsinki - Ethical principles for medical
13 research involving human subjects, 1964.
14 28. Swiss Academy of Medical Sciences. Guideline - Concerning scientific research involving
15 human beings 2009.
16 29. The Federal Authorities of the Swiss Confederation. Bundesgesetz über den
17 Datenschutz (DSG) vom 19. Juni 1992, Stand 01.01.2011, 1992.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Groups	Inclusion criteria	Exclusion criteria
All subjects	<ul style="list-style-type: none"> ▪ Right-handed ▪ Gender (female and male) ▪ Age limits: 18-55 years ▪ MR suitability ▪ Written informed consent 	<ul style="list-style-type: none"> ▪ Pregnancy or breast feeding ▪ Any craniocerebral injury or surgery ▪ Any permanent ferromagnetic implant ▪ Any previous surgery of LUT / genitalia ▪ Any anatomical anomaly of LUT / genitalia ▪ Any LUT malignancy ▪ PVR > 150mL
Healthy controls	<ul style="list-style-type: none"> ▪ Unimpaired LUT function ▪ No LUTS (3-day bladder diary) <ul style="list-style-type: none"> ▪ ≤ 3 episodes of urinary urgency / week ▪ Urinary frequency < 8 / 24h 	<ul style="list-style-type: none"> ▪ Impaired LUT function ▪ UTI ▪ Any LUTS (3-day bladder diary) <ul style="list-style-type: none"> ▪ ≥ 3 episodes of urinary urgency / week ▪ Urinary frequency > 8 / 24h
MS patients without LUTS	<ul style="list-style-type: none"> ▪ Diagnosis of MS according to the McDonald criteria ▪ EDSS ≤ 6 ▪ No LUTS (3-day bladder diary) <ul style="list-style-type: none"> ▪ ≤ 3 episodes of urinary urgency / week ▪ Urinary frequency < 8 / 24h 	<ul style="list-style-type: none"> ▪ Any neurological or psychological disease other than MS ▪ Any metabolic disease ▪ Any concomitant treatment for the LUT (e.g. neuromodulation) ▪ SUI ▪ UTI ▪ Any LUTS (3-day bladder diary) <ul style="list-style-type: none"> ▪ ≥ 3 episodes of urinary urgency / week ▪ Urinary frequency > 8 / 24h
MS patients with LUTS	<ul style="list-style-type: none"> ▪ Diagnosis of MS according to the McDonald criteria ▪ EDSS ≤ 6 ▪ LUTS > 6 months (3-day bladder diary) <ul style="list-style-type: none"> ▪ ≥ 3 episodes of urinary urgency / week ▪ Urinary frequency > 8 / 24h 	<ul style="list-style-type: none"> ▪ Any neurological or psychological disease other than MS ▪ Any metabolic disease ▪ Any concomitant treatment for the LUT (e.g. neuromodulation) ▪ SUI ▪ UTI ▪ Any condition other than MS that might explain LUTS ▪ Indwelling catheters or necessity to perform ISC
Patients with non-neurogenic LUTS	<ul style="list-style-type: none"> ▪ LUTS > 6 months (3-day bladder diary) <ul style="list-style-type: none"> ▪ ≥ 3 episodes of urinary urgency / week ▪ Urinary frequency > 8 / 24h 	<ul style="list-style-type: none"> ▪ Any neurological, psychological, metabolic, or cardiovascular disease ▪ Any concomitant treatment for the LUT (e.g. neuromodulation) ▪ SUI ▪ UTI ▪ Indwelling catheters or necessity to perform ISC

Table 1 – Inclusion and exclusion criteria for all subjects.

MR = Magnet resonance, LUT = Lower urinary tract, LUTS = LUTS symptoms, MS = Multiple sclerosis, EDSS = Expanded Disability Status Scale, PVR = Post void residual, UTI = Urinary tract infection, SUI = Stress urinary incontinence, ISC = Intermittent self-catheterization

Figure legends

Figure 1 – Timetable and characteristics of all four visits.

PVR = Post void residual, LUTS = Lower urinary tract symptoms, ICIQ = International consultation on incontinence modular questionnaire, QoL = Quality of life

Figure 2 – Schematic protocol of operational sequences of magnetic resonance imaging (MRI) measurements including functional MRI (fMRI): A) 1st and 3rd MRI measurement and B) 2nd MRI measurement.


VBM = Voxel-based morphometry, DTI = Diffusion tensor imaging, RS-fMRI = Resting-State fMRI

Figure 3 – Schematic diagram of the scan paradigm of four different functional magnetic resonance imaging (fMRI) tasks at visits 2, 3, and 4. All fMRI tasks consist of 8 repetitive blocks, each with either 6 (task 1 and 4) or 7 (task 2 and 3) conditions.

A) Conditions of the 1st fMRI task: 1) rest (no specific stimulus or task is performed), 2) automated infusion of 100mL warm (37°C) saline, 3) rating of desire to void and level of pain, 4) short rest, 5) passive withdrawal to empty the bladder completely, and 6) rest. This task starts with an empty bladder and will be performed in patients with LUTS without any underlying neurologic disease and in MS patients with LUTS at visits 2, 3, and 4 (every MRI measurement), whereas in healthy controls only at visit 3 (2nd MRI measurement).


B and C) Conditions of the 2nd and 3rd fMRI task: 1) rest, 2) automated infusion of 100 mL warm saline, 3) rating of desire to void and level of pain, 4) short rest, 5) automated withdrawal of 100mL, 6) rating of desire to void and level of pain, and 7) rest. The 2nd task starts with a low prefilled bladder volume (100mL) and will be performed in MS patients without LUTS and in healthy controls at visit 2 and 3 (1st and 2nd MRI measurement). The 3rd task starts with a high prefilled bladder volume (until a persistent desire to void) and will be performed in all subjects (patients and healthy controls) during visit 2 and 3 (1st and 2nd MRI measurement). Additionally, this task will be carried out in patients with LUTS without any underlying neurologic disease and MS patients with LUTS at visit 4 (3rd MRI measurement).

D) Conditions of the 4th fMRI task: 1) rest, 2) automated infusion of 100mL cold (4-8°C) saline, 3) rating of desire to void and level of pain, 4) short rest, 5) passive withdrawal to empty the bladder completely, and 6) rest. This task starts with an empty bladder and will be performed in all subjects (patients and healthy controls) during visit 2 and 3 (1st and 2nd MRI measurement). Additionally, this task will be executed in patients with LUTS without any underlying neurologic disease and MS patients with LUTS at visit 4 (3rd MRI measurement).



Timetable and characteristics of all four visits.


PVR = Post void residual, LUTS = Lower urinary tract symptoms, ICIQ = International consultation on incontinence modular questionnaire, QoL = Quality of life
 254x190mm (72 x 72 DPI)




Schematic protocol of operational sequences of magnetic resonance imaging (MRI) measurements including functional MRI (fMRI): A) 1st and 3rd MRI measurement and B) 2nd MRI measurement.

VBM = Voxel-based morphometry, DTI = Diffusion tensor imaging, RS-fMRI = Resting-State fMRI 190x275mm (72 x 72 DPI)


A) Task 1 – Automated, repetitive bladder filling with 100mL warm (37°C) saline starting with an empty bladder.



B) Task 2 – Automated, repetitive bladder filling with 100mL warm saline starting with a low prefilled bladder volume (100mL).



C) Task 3 – Automated, repetitive bladder filling with 100mL warm saline starting with a high prefilled bladder volume (until a persistent desire to void).



D) Task 4 – Automated, repetitive bladder filling with 100mL cold (4-8 °C) saline starting with an empty bladder.



Schematic diagram of the scan paradigm of four different functional magnetic resonance imaging (fMRI) tasks at visits 2, 3, and 4. All fMRI tasks consist of 8 repetitive blocks, each with either 6 (task 1 and 4) or 7 (task 2 and 3) conditions.

A) Conditions of the 1st fMRI task: 1) rest (no specific stimulus or task is performed), 2) automated infusion of 100mL warm (37°C) saline, 3) rating of desire to void and level of pain, 4) short rest, 5) passive withdrawal to empty the bladder completely, and 6) rest. This task starts with an empty bladder and will be performed in patients with LUTS without any underlying neurologic disease and in MS patients with LUTS at visits 2, 3, and 4 (every MRI measurement), whereas in healthy controls only at visit 3 (2nd MRI measurement).

B and C) Conditions of the 2nd and 3rd fMRI task: 1) rest, 2) automated infusion of 100 mL warm saline, 3) rating of desire to void and level of pain, 4) short rest, 5) automated withdrawal of 100mL, 6) rating of desire to void and level of pain, and 7) rest. The 2nd task starts with a low prefilled bladder volume (100mL) and will be performed in MS patients without LUTS and in healthy controls at visit 2 and 3 (1st and 2nd MRI

1
2
3 measurement). The 3rd task starts with a high prefilled bladder volume (until a persistent desire to void)
4 and will be performed in all subjects (patients and healthy controls) during visit 2 and 3 (1st and 2nd MRI
5 measurement). Additionally, this task will be carried out in patients with LUTS without any underlying
6 neurologic disease and MS patients with LUTS at visit 4 (3rd MRI measurement).
7 D) Conditions of the 4th fMRI task: 1) rest, 2) automated infusion of 100mL cold (4-8°C) saline, 3) rating of
8 desire to void and level of pain, 4) short rest, 5) passive withdrawal to empty the bladder completely, and 6)
9 rest. This task starts with an empty bladder and will be performed in all subjects (patients and healthy
10 controls) during visit 2 and 3 (1st and 2nd MRI measurement). Additionally, this task will be executed in
11 patients with LUTS without any underlying neurologic disease and MS patients with LUTS at visit 4 (3rd MRI
12 measurement).
13 190x275mm (72 x 72 DPI)

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open

Protocol for a prospective neuro-imaging study investigating the supraspinal control of lower urinary tract function in healthy controls and patients with non-neurogenic lower urinary tract symptoms

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004357.R1
Article Type:	Protocol
Date Submitted by the Author:	23-Apr-2014
Complete List of Authors:	Walter, Matthias; Spinal Cord Injury Center & Research, University of Zurich, Neuro-Urology Michels, Lars; University Hospital Zurich, Institute of Neuroradiology Kollias, Spyros; University Hospital Zurich, Institute of Neuroradiology van Kerrebroeck, Philip; University Hospital Maastricht, Department of Urology Kessler, Thomas; Spinal Cord Injury Center & Research, University of Zurich, Neuro-Urology Mehnert, Ulrich; Spinal Cord Injury Center & Research, University of Zurich, Neuro-Urology
Primary Subject Heading:	Urology
Secondary Subject Heading:	Radiology and imaging
Keywords:	Neuro-urology < UROLOGY, Bladder disorders < UROLOGY, Urinary incontinences < UROLOGY, Neuroradiology < RADIOLOGY & IMAGING

SCHOLARONE™
Manuscripts

1
2
3 **Protocol for a prospective neuro-imaging study investigating the supraspinal control**
4 **of lower urinary tract function in healthy controls and patients with non-neurogenic**
5 **lower urinary tract symptoms**
6
7

8
9 Matthias Walter¹, Lars Michels², Spyros Kollias², Philip E. van Kerrebroeck³, Thomas M.
10 Kessler¹, Ulrich Mehnert¹
11

12
13 ¹ Neuro-Urology, Spinal Cord Injury Centre & Research, University of Zürich, Balgrist
14 University Hospital, Zürich, Switzerland

15
16 ² Institute of Neuro-Radiology, University of Zürich, University Hospital Zürich, Zürich,
17 Switzerland
18

19
20 ³ Department of Urology, University Hospital Maastricht, Maastricht, The Netherlands
21

22
23 Corresponding author: Ulrich Mehnert, M.D.
24 Neuro-Urology
25 Spinal Cord Injury Center & Research
26 University of Zürich
27
28

29
30 Balgrist University Hospital

31 Forchstrasse 340

32 8008 Zürich

33 Switzerland
34

35
36 Phone: +41 44 386 37 21

37
38 Fax: +41 44 386 37 31

39
40 Email: ulrich.mehnert@paralab.balgrist.ch
41

42
43 Keywords: Neuro-Urology, bladder disorders, urinary incontinence, neuroradiology
44

45
46 Word count (excluding title page, abstract, references, figures and tables): 2826
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Lower urinary tract symptoms (LUTS) are highly prevalent, cause an enormous economic burden on health care systems, and significantly impair quality of life (QoL) of affected patients. The dependence of the lower urinary tract (LUT) on complex central neuronal circuits makes it unique in comparison to other visceral functions, such as the gastrointestinal tract, but also more vulnerable to neurological diseases.

Methods & analysis: This is a prospective neuro-imaging study investigating the supraspinal control of LUT function in healthy controls and patients with non-neurogenic LUTS.

The clinical assessment will include medical history, neuro-urological examination, bladder diary, urine analysis, urodynamic investigations, as well as standardized questionnaires regarding LUTS and QoL.

The acquisition of neuro-imaging data will include structural assessments (T1-weighted imaging and diffusion tensor imaging (DTI)) as well as functional investigations using blood-oxygen-level-dependent (BOLD) sensitive functional magnetic resonance imaging (fMRI) in a 3 Tesla MR scanner. The fMRI will be performed during four different bladder tasks using an automated MR-compatible and MR-synchronised pump system. The first three task-related fMRIs will consist of automated, repetitive filling of 100mL warm (37°C) saline starting with (1) an empty bladder, (2) a low prefilled bladder volume (100mL), and (3) a high prefilled bladder volume (persistent desire to void). The 4th task-related fMRI will comprise of automated, repetitive filling of 100mL cold (4-8°C) saline starting with an empty bladder.

Ethics & dissemination:

The local ethics committee approved this study (KEK-ZH-Nr. 2011-0346). The findings of the study will be published in peer-reviewed journals and presented at national and international scientific meetings.

Trial registration:

This study has been registered at [clinicaltrials.gov](http://www.clinicaltrials.gov) (<http://www.clinicaltrials.gov/ct2/show/NCT01768910>).

ARTICLE SUMMARY

Study focus

- To demonstrate correlations between alterations in brain structural and functional connectivity in relation to LUT control and LUTS, i.e. urgency with or without urgency urinary incontinence, and urinary frequency.
- To compare clinical correlates of treatment efficacy in patients with non-neurogenic LUTS with the associated changes in brain activity and connectivity.

Key messages

- Although recent neuro-imaging studies in humans and neuro-physiological animal studies have contributed to establish concepts of spinal and supraspinal LUT control, the exact pathophysiological mechanisms involved in human LUTS are still largely unknown.
- A multimodal neuro-imaging approach has considerable potential to broaden our knowledge of the supraspinal LUT control, and helps to adapt current concepts of LUT control.

Strengths and limitations of this study

- This will be the first study to identify brain networks of supraspinal LUT control in healthy subjects and abnormalities within such brain networks in patients with non-neurogenic LUTS using structural and functional MRI techniques in correlation with clinical measurements.
- Investigation of test-retest reliability which has not yet been performed for neuroimaging of LUT tasks. However, this is important especially in regard to interpretation of treatment effects.

INTRODUCTION

Lower urinary tract symptoms (LUTS) are highly prevalent, i.e. about 11% in the worldwide population in 2008, and forecasted to increase up to 20% until 2018.^{1 2} Moreover, LUTS cause an enormous economic burden on each health care system,^{3 4} i.e. comparable to diabetes mellitus,⁵ and significantly impair the quality of life (QoL) of affected patients.^{6 7}

For a proper functioning, lower urinary tract (LUT) structures, i.e. bladder, bladder neck, urethra, and urethral sphincter, rely on intact neuronal innervations that are under control of a complex supraspinal network.⁸⁻¹⁰ The dependence of the LUT on such complex central neuronal circuits makes it unique in comparison to other visceral functions, e.g. gastrointestinal tract, but also more vulnerable to neurological diseases.¹⁰

Recent neuro-imaging studies have shown that patients with neurological disorders such as Parkinson's disease (PD)¹¹⁻¹³ and spinal cord injury (SCI)¹⁴ demonstrate different supraspinal activity patterns compared to healthy controls in response to LUT stimulation tasks, which might represent a neural correlate to their LUTS.

Although there are several concepts regarding the human LUT function and neuronal control in normal and pathological conditions, the exact pathophysiological mechanisms involved remain largely unknown.⁹ Despite the popularity of resting-state functional magnetic resonance imaging (RS-fMRI)¹⁵⁻²⁰ and diffusion tensor imaging (DTI)²¹ in other fields in neuroscience, these techniques have not been applied in the context of supraspinal LUT control. There are only two DTI studies published in regard to LUT control in general: (1) a case report by Theadin et al.²² studying spinal cord infarctions and clinical symptoms and (2) a prospective study by van der Jagt et al.²³ investigating architectural configuration and microstructural properties of the sacral plexus.

As cortical and sub-cortical (e.g. brainstem) brain regions are crucial for voluntary LUT control^{10 24 25}, investigation of the supraspinal regions with high-resolution imaging techniques, i.e. fMRI, can significantly contribute to increase our understanding on the effects of supraspinal lesions and alterations related to LUTS.^{10 26}

In this study, we are aiming to identify supraspinal areas associated with LUT control in healthy subjects and in patients with non-neurogenic LUTS. Task-related blood-oxygen-level-dependent (BOLD) and RS-fMRI will be applied as well as structural MRI (T1-weighted MRI and DTI). Hence, we will examine if bladder processing is already altered on the structural level, and on baseline (RS-fMRI) functional connectivity. For example, the multiple repetition of the RS-fMRI will help to understand whether manipulation of sensory perception (induced by infusion and withdrawal) will alter the default mode network²⁰ of the brain. Furthermore, we can examine volumetric parameters (e.g. gray matter concentration) by voxel-based morphometry (VBM)²⁷, structural integrity and connectivity of white matter tracts (DTI) as well as functional connectivity (FC).

1
2
3 This unique and detailed multimodal imaging protocol should pinpoint to structural and
4 functional processing units involved during supraspinal LUT control and should identify all
5 dysfunctional neuronal components in patients with disturbed LUT control.
6

7 Importantly, we will investigate the reliability²⁸ of BOLD signals in task-related fMRI and RS-
8 fMRI in healthy subjects and patients with non-neurogenic LUTS. The test-retest validation,
9 i.e. the intra-class correlation coefficient (ICC) for absolute or consistent agreement of
10 subject activations from visit to visit, has not been evaluated in regard to the supraspinal LUT
11 control yet.
12
13
14

15 16 17 **METHODS AND ANALYSIS**

18 19 **Study design**

20 This prospective research study will be conducted at the University of Zürich, Zürich,
21 Switzerland.
22
23
24

25 26 **Study population & recruitment**

27 According to the inclusion and exclusion criteria (Table 1), we will investigate patients with
28 non-neurogenic LUTS and healthy controls with an unimpaired LUT function. Subjects of
29 both groups will be matched according to age and gender.
30

31 Patients with non-neurogenic LUTS will be recruited from our own department (Neuro-
32 Urology, Balgrist University Hospital Zürich) and through our partners at the University
33 Hospital Zürich and the Triemli Hospital Zürich. Eligible patients with non-neurogenic LUTS
34 and healthy controls will be invited to a first visit (screening) during which detailed information
35 about the study, in particular the aims, methods, possible risks, and side effects, will be
36 given. After obtaining written informed consent, the following data will be collected: medical
37 history, a 3-day bladder diary, urine sample to exclude urinary tract infection (UTI) and
38 pregnancy in female subjects, urodynamic parameters, and post void residual measured by
39 ultrasound as well as standardized questionnaires regarding LUTS and QoL. The validated
40 German versions of these questionnaires will be used with permission of the International
41 consultation on incontinence modular questionnaire [(ICIQ), Bristol Urological Institute,
42 Southmead Hospital Bristol, UK], and will address the LUTS (ICIQ-LUTS) in both females
43 (ICIQ-FLUTS) and males (ICIQ-MLUTS) whereas the ICIQ-LUTSQoL will display the QoL in
44 regard to LUTS.
45
46
47
48
49
50
51
52

53 54 55 **Determination of sample size**

56 A power analysis was conducted using G*Power (www.gpower.hhu.de). In order to have
57 sufficient power (0.80) to detect a large effect size (0.80) between healthy subjects and
58
59
60

1
2
3 patients with non-neurogenic LUTS (significance level 0.05), at least 21 participants per
4 group need to be recruited. To demonstrate post-treatment effects in patients with non-
5 neurogenic LUTS compared to their baseline using the same power, effect size and
6 significance level, at least 12 participants for each treatment option are necessary. These
7 sample sizes are in line with earlier studies^{22 23} including our own^{14 29}, which provided
8 statistical evidence using small collectives, i.e. between 12 and 21 subjects.
9
10
11
12

13 **Study location**

- 14 ▪ Neuro-Urology, Spinal Cord Injury Centre & Research, University of Zürich, Balgrist
15 University Hospital, Zürich, Switzerland
- 16 ▪ MR-Centre, University Hospital Zürich, Zürich, Switzerland

17 **Partners**

- 18 ▪ NeuroRadiology Clinic, University Hospital Zürich, Zürich, Switzerland
- 19 ▪ Departments of Urology and Gynaecology, University Hospital Zürich, Zürich,
20 Switzerland
- 21 ▪ Department of Urology and Gynaecology, Triemli Hospital, Zürich, Switzerland

22 **Investigations**

23 Following screening and study inclusion, all subjects will be scheduled for the 2nd and 3rd visit
24 (1st and 2nd MRI measurement) at the MR-Centre. Patients with non-neurogenic LUTS will
25 return for a 4th visit (3rd MRI measurement), either after receiving treatment for LUTS or
26 without treatment acting as a direct control group within the patient cohort (Figure 1).
27

28 All MR measurements (Figure 2) will be performed using a Philips Ingenia 3 Tesla MR
29 scanner (Philips Medical Systems, Best, The Netherlands) with a 16-channel head coil.
30 During the 2nd visit, we will acquire the following neuro-imaging data. Structural
31 measurements will contain T1-weighted MRI and DTI. The functional measurements will
32 comprise of RS-fMRI and task-related fMRI. Four different RS-fMRI will be applied, i.e. (1) at
33 baseline with an empty bladder, (2) with an empty bladder plus transurethral catheter, (3)
34 with a low prefilled bladder (100mL saline, body warm) prior to task-related fMRI, and (4)
35 after a task-related fMRI, to understand whether manipulation of sensory perception (induced
36 by catheter or prefilling) will alter the default mode network.²⁰ The task-related fMRI will be
37 acquired during four different bladder tasks (Figure 3). In order to precisely fill and drain the
38 bladder (i.e. specific volume and duration of time), we designed an automated MR-
39 compatible and MR-synchronised pump system. In the first three task-related fMRI, we will
40 examine the effect of visceral bladder sensation by automated, repetitive filling with 100mL
41 body warm saline starting with (1) an empty bladder, (2) a low prefilled bladder, and (3) a
42 high prefilled bladder (persistent desire to void). The 4th task-related fMRI will consist of
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 automated, repetitive filling of 100mL cold (4-8°C) saline starting with an empty bladder to
4 investigate the neural correlates of cold bladder sensation (Figure 3). Subjects will rate their
5 desire to void and their level of pain using a displayed visual analogue scale and an fMRI-
6 compatible handheld response system.³⁰

7
8
9 During the 2nd MRI measurement (3rd visit, 1 to 4 weeks later), we will utilise a selection of
10 MRI measurements for the purpose of reliability analysis²⁸, i.e. RS-fMRI (baseline with an
11 empty bladder plus transurethral catheter), and task-related fMRI to compare within and
12 between groups.

13
14
15 The 3rd MRI measurement will be identical to the 1st MRI measurement to evaluate post
16 versus pre-treatment effects in patients with non-neurogenic LUTS. The time from the start of
17 treatment to the 4th visit, i.e. 5 to 7 weeks (Figure 1), is necessary to let clinical improvements
18 develop.^{31 32}

21 22 23 **Safety**

24 The staff involved in this study will be instructed and trained according to the safety
25 regulations of the MR-Centre of the University Hospital Zürich. All subjects will be asked to
26 remove any ferromagnetic items, e.g. bra, earrings, chains, rings, and piercings prior to
27 entering the scanner room. All subjects will be provided with standardised clinical scrubs
28 instead of wearing their own clothes. Before every MR measurement (visit 2, 3 and 4), urine
29 samples will be analysed from every subject in order to exclude UTI or pregnancy. In case of
30 pregnancy, the subject will be excluded from the study and referred to a gynaecologist. In
31 case of UTI, the subject will not undergo the experiment, but will receive immediate antibiotic
32 treatment if the UTI is symptomatic or treatment depending on further microbiological urine
33 analysis in the absence of UTI symptoms. The subject can be reassigned to the study, if the
34 microbiological urine analysis shows no evidence of an UTI or the UTI has been successfully
35 treated.

36
37
38 In the situation of an adverse event (AE) or a severe adverse event (SAE), as defined by the
39 international conference on harmonisation (ICH) good clinical practice (GCP) guidelines
40 (E6)³³ and international organization for standardization (ISO, 14155)³⁴, appropriate actions
41 will be executed and the according body (principle investigator, ethics committee) will be
42 informed. All AEs and SAEs will be followed as long as medically indicated.

43 44 45 46 47 48 49 50 51 52 **Study outcome measures**

53 **Primary**

- 54
55 (A) BOLD signal intensity changes in a priori supraspinal regions of interest (ROI), e.g.
56 pons, insula, anterior cingulate cortex, thalamus, hypothalamus, supplementary motor
57 area, and prefrontal cortex, during task-related fMRI in relation to the specific
58
59
60

1
2
3 condition, i.e. infusion or to a contrast, i.e. low versus full bladder volume, during two
4 (healthy controls) or three (patients with non-neurogenic LUTS) visits.

5
6 The precise selection of ROIs will be based on the coordinates of the peak activations
7 during task-related fMRI, i.e. taken from the MNI space.

- 8
9 (B) Reliability of BOLD signal changes during RS-fMRI and task-related fMRI across
10 visits (e.g. 2nd and 3rd visit) in healthy subjects and patients with non-neurogenic
11 LUTS.
12
13 (C) BOLD signal changes in supraspinal ROIs during task-related fMRI in patients with
14 non-neurogenic LUTS before and after treatment to quantify the link between BOLD
15 signal changes and treatment efficacy.
16
17

18 19 20 Secondary

- 21 (A) Structural differences, i.e. between healthy subjects and patients with non-neurogenic
22 LUTS, and changes, i.e. post vs pre-treatment state, of gray matter concentration
23 using VBM.
24
25 (B) Structural (SC) and functional connectivity (FC) between supraspinal ROIs, e.g.
26 insula, cingulate, and prefrontal cortices, and to identify specific alterations with DTI³⁵,
27 i.e. whole-brain fractional anisotropy (FA) and mean diffusivity (MD) comparison
28 between healthy subjects and patients with non-neurogenic LUTS (incl. post vs pre-
29 treatment changes) as well as probabilistic tractography between ROIs (white matter
30 fibre structure).
31
32 (C) Differences of BOLD signals during RS-fMRI between healthy subjects and patients
33 with non-neurogenic LUTS (incl. post vs pre-treatment changes), i.e. intra- and
34 interhemispheric connectivity³⁶ whether these signals already differ at baseline, are
35 influenced by the presence of a catheter, by prefilling and/or by task-related fMRI.
36
37 (D) Clinical scores (e.g. bladder volume, urodynamic parameters, and level of desire to
38 void during fMRI) will be correlated to BOLD signal changes as well as to structural
39 markers (e.g. grey matter volume or number of white matter tracts between ROIs)
40 using regression analyses.
41
42
43
44
45
46
47

48 49 Data analysis

50 Clinical data, e.g. urodynamic parameters, 3-day bladder diary outcome, and questionnaires
51 scores, will be statistically analysed and compared between groups using IBM's Statistical
52 Package for the Social Sciences (SPSS) version 19.0 or newer (Armonk, New York, U.S.)
53 and will be presented with means and standard deviations or with medians and interquartile
54 ranges as appropriate.
55
56
57
58
59
60

1
2
3 The neuro-imaging data will be analysed using statistical parametric mapping (SPM) version
4 12 (Wellcome Department of Imaging Neuroscience, University College London, UK).
5 Preprocessing of functional data from each task-related fMRI will be done for each
6 participant individually. The images will be realigned to the first scan, unwarped to control for
7 movement- and susceptibility-induced image distortions³⁷, spatially coregistered to the T1-
8 weighted image, and normalized to the Montreal Neurologic Institute (MNI) anatomical
9 standard space. At last, the functional data will be smoothed spatially with an isotropic
10 Gaussian kernel. Thereafter, first-level analysis using the general linear model (GLM) will
11 performed to create contrasts of interest, e.g. low vs full bladder or infusion vs withdrawal.³⁸
12 The six movement parameters will be modeled as additional regressors to control for
13 potential head motion.

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Second-level factorial design will include at least (1) one-sample t-tests to compute a mean for each group, (2) two-sample t-tests to compare healthy subjects and patients with non-neurogenic LUTS and (3) paired t-tests to evaluate post- vs. pre-treatment effects in patients with non-neurogenic LUTS. The ICC for task-related and RS-fMRI reliability will be analyzed using the SPM-compatible ICC toolbox (<http://www.kcl.ac.uk/iop/depts/neuroimaging/research/imaginganalysis/Software/ICC-Toolbox.aspx>).

Association of individual (clinical) variables with BOLD signal changes will be assessed by whole-brain and ROIs-based correlation analyses (correlation coefficients will be reported). DTI data will be analysed using TBSS (<http://fsl.fmrib.ox.ac.uk/fsl/fsl4.0/tbss/index>) and BrainVoyager (<http://www.brainvoyager.com/downloads/downloads.html>) with the following established DTI analyses: Whole-brain fractional anisotropy (FA) and mean diffusivity (MD) comparison between groups as well as probabilistic tractography between ROIs. Seed and target regions, i.e. ROIs will be defined (1) a priori using anatomic coordinates, e.g. from the SPM toolbox WFU_PickAtlas (<http://fmri.wfubmc.edu/software/PickAtlas>) and (2) from peak activations acquired from task-related fMRI and RS-fMRI on the standard MNI space. Volumetric changes in gray and white matter will be analyzed using voxel-based morphometry (VBM), e.g. the VBM toolbox (<http://dbm.neuro.uni-jena.de/vbm>) in SPM.

ETHICS AND DISSEMINATION

This cohort study will be performed in accordance to the World Medical Association Declaration of Helsinki³⁹ and the guidelines of the Swiss Academy of Medical Sciences.⁴⁰

This study has been approved by the local ethics committee (Kantonale Ethikkommission Zürich, KEK-ZH-Nr. 2011-0346). Furthermore, handling of all personal data will strictly comply with the federal law of data protection in Switzerland.⁴¹

This study has been registered at [clinicaltrials.gov](http://www.clinicaltrials.gov) (<http://www.clinicaltrials.gov/ct2/show/NCT01768910>).

DISCUSSION

This study will investigate supraspinal LUT control in healthy subjects and patients with non-neurogenic LUTS using a multimodal imaging protocol, i.e. structural (T1-weighted and DTI) and fMRI (RS-fMRI and task-related fMRI), to examine hemodynamic responses to LUT stimulation. From the acquired neuro-imaging data, structural (SC) and functional connectivity (FC), and structural integrity evaluation of white matter tracts and gray matter concentration (VBM) will be analysed to identify specific alterations of the supraspinal LUT control. In addition, effects on the supraspinal LUT control after treatment for LUTS (e.g. antimuscarinergics or botulinum toxin) will be investigated. It is expected that this study will provide new insights into the supraspinal neuronal mechanisms and networks responsible for LUT control. The findings will help to verify, amend, or adjust neuronal circuitry models established from findings in healthy subjects, now in the context of patients with non-neurogenic LUTS. Particularly, the use of newer imaging and evaluation techniques has the potential to serve as quantifiable outcome measures for therapy success and provide evidence for non-responders of LUTS treatment.

Acknowledgements

We would like to acknowledge the Swiss National Science Foundation, SwissLife Jubiläumsstiftung, and Swiss Continenence Foundation for financial support. Furthermore, we would like to thank our partners contributing to this study: Departments of Urology and Gynaecology of the University Hospital Zürich and Departments of Urology and Gynaecology, Triemli Hospital, Zürich, Switzerland.

We thank Behnaz Jarrahi for granting figure contents.

Funding

Swiss National Science Foundation (grant number: 135774)

SwissLife Jubiläumsstiftung

Swiss Continenence Foundation

Contributors

All authors participated in creating the study design.

MW and UM drafted the manuscript.

LM, SK, PEVK and TMK critically reviewed the manuscript.

UM, SK and TMK obtained the funding of this study.

All the authors read and approved the final manuscript.

Competing interests

There are no competing interests.

REFERENCES

1. Irwin DE, Kopp ZS, Agatep B, et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. *BJU Int* 2011;108(7):1132-8.
2. Irwin DE, Milsom I, Hunzkaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. *Eur Urol* 2006;50(6):1306-14; discussion 14-5.
3. Ganz ML, Smalarz AM, Krupski TL, et al. Economic costs of overactive bladder in the United States. *Urology* 2010;75(3):526-32, 32 e1-18.
4. Klotz T, Bruggenjurgan B, Burkart M, et al. The economic costs of overactive bladder in Germany. *Eur Urol* 2007;51(6):1654-62; discussion 62-3.
5. Hampel C, Gillitzer R, Pahernik S, et al. [Epidemiology and etiology of overactive bladder]. *Urologe A* 2003;42(6):776-86.
6. Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. *BJU Int* 2008;101(11):1388-95.
7. Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. *BJU Int* 2006;97(1):96-100.
8. Blok BF. Brain control of the lower urinary tract. *Scand J Urol Nephrol Suppl* 2002(210):11-5.
9. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. *Nat Rev Neurosci* 2008;9(6):453-66.
10. Fowler CJ, Griffiths DJ. A decade of functional brain imaging applied to bladder control. *NeuroUrol Urodyn* 2010;29(1):49-55.
11. Herzog J, Weiss PH, Assmus A, et al. Subthalamic stimulation modulates cortical control of urinary bladder in Parkinson's disease. *Brain* 2006;129(Pt 12):3366-75.
12. Herzog J, Weiss PH, Assmus A, et al. Improved sensory gating of urinary bladder afferents in Parkinson's disease following subthalamic stimulation. *Brain* 2008;131(Pt 1):132-45.
13. Kitta T, Kakizaki H, Furuno T, et al. Brain activation during detrusor overactivity in patients with Parkinson's disease: a positron emission tomography study. *J Urol* 2006;175(3 Pt 1):994-8.
14. Mehnert U, Michels L, Zempleni MZ, et al. The supraspinal neural correlate of bladder cold sensation--an fMRI study. *Hum Brain Mapp* 2011;32(6):835-45.
15. Biswal BB, Van Kylen J, Hyde JS. Simultaneous assessment of flow and BOLD signals in resting-state functional connectivity maps. *NMR Biomed* 1997;10(4-5):165-70.
16. Cauda F, Costa T, Torta DM, et al. Meta-analytic clustering of the insular cortex: characterizing the meta-analytic connectivity of the insula when involved in active tasks. *Neuroimage* 2012;62(1):343-55.
17. Greicius MD, Supekar K, Menon V, et al. Resting-state functional connectivity reflects structural connectivity in the default mode network. *Cereb Cortex* 2009;19(1):72-8.
18. Gusnard DA, Akbudak E, Shulman GL, et al. Medial prefrontal cortex and self-referential mental activity: relation to a default mode of brain function. *Proc Natl Acad Sci U S A* 2001;98(7):4259-64.
19. Gusnard DA, Raichle ME. Searching for a baseline: functional imaging and the resting human brain. *Nat Rev Neurosci* 2001;2(10):685-94.
20. Raichle ME, MacLeod AM, Snyder AZ, et al. A default mode of brain function. *Proc Natl Acad Sci U S A* 2001;98(2):676-82.
21. Basser PJ, Mattiello J, LeBihan D. MR diffusion tensor spectroscopy and imaging. *Biophys J* 1994;66(1):259-67.

- 1
- 2
- 3 22. Theaudin M, Saliou G, Denier C, et al. A correlation between fractional anisotropy
- 4 variations and clinical recovery in spinal cord infarctions. *J Neuroimaging*
- 5 2013;23(2):256-8.
- 6 23. van der Jagt PK, Dik P, et al. Architectural configuration and microstructural properties of
- 7 the sacral plexus: a diffusion tensor MRI and fiber tractography study. *Neuroimage*
- 8 2012;62(3):1792-9.
- 9 24. Andrew J, Nathan PW. Lesions on the Anterior Frontal Lobes and Disturbances of
- 10 Micturition and Defaecation. *Brain* 1964;87:233-62.
- 11 25. Holstege G. Micturition and the soul. *J Comp Neurol* 2005;493(1):15-20.
- 12 26. de Groat WC. A neurologic basis for the overactive bladder. *Urology* 1997;50(6A
- 13 Suppl):36-52; discussion 53-6.
- 14 27. Ashburner J, Friston KJ. Voxel-based morphometry--the methods. *Neuroimage*
- 15 2000;11(6 Pt 1):805-21.
- 16 28. Caceres A, Hall DL, Zelaya FO, et al. Measuring fMRI reliability with the intra-class
- 17 correlation coefficient. *Neuroimage* 2009;45(3):758-68.
- 18 29. Michels L, Mehnert U, Boy S, et al. The somatosensory representation of the human
- 19 clitoris: an fMRI study. *Neuroimage* 2010;49(1):177-84.
- 20 30. Jarrahi B, Wanek J, Mehnert U, et al. An fMRI-compatible multi-configurable handheld
- 21 response system using an intensity-modulated fiber-optic sensor. *Conf Proc IEEE*
- 22 *Eng Med Biol Soc* 2013;2013:6349-52.
- 23 31. Agency for Healthcare Research and Quality. Treatment of Overactive Bladder in
- 24 Women, 2009.
- 25 32. Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder
- 26 (non-neurogenic) in adults: AUA/SUFU guideline. *J Urol* 2012;188(6 Suppl):2455-63.
- 27 33. International conference on harmonisation. Good clinical practice guideline, 1996.
- 28 34. International organization for standardization. ISO 14155, 2011.
- 29 35. Kucyi A, Moayedi M, Weissman-Fogel I, et al. Hemispheric asymmetry in white matter
- 30 connectivity of the temporoparietal junction with the insula and prefrontal cortex.
- 31 *PLoS One* 2012;7(4):e35589.
- 32 36. Maldjian JA, Davenport EM, Whitlow CT. Graph Theoretical Analysis of Resting-State
- 33 MEG data: Identifying Interhemispheric Connectivity and the Default Mode.
- 34 *Neuroimage* 2014.
- 35 37. Andersson JL, Hutton C, Ashburner J, et al. Modeling geometric deformations in EPI time
- 36 series. *Neuroimage* 2001;13(5):903-19.
- 37 38. Friston KJ, Holmes AP, Poline JB, et al. Analysis of fMRI time-series revisited.
- 38 *Neuroimage* 1995;2(1):45-53.
- 39 39. World Medical Association. Declaration of Helsinki - Ethical principles for medical
- 40 research involving human subjects, 1964.
- 41 40. Swiss Academy of Medical Sciences. Guideline - Concerning scientific research involving
- 42 human beings, 2009.
- 43 41. The Federal Authorities of the Swiss Confederation. Bundesgesetz über den
- 44 Datenschutz (DSG) vom 19. Juni 1992, Stand. 01.01.2011, 1992.
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Figure legends

Figure 1 – Timetable and characteristics of all four visits.

PVR = Post void residual, LUTS = Lower urinary tract symptoms, QoL = Quality of life

Figure 2 – Schematic protocol of operational sequences of magnetic resonance imaging (MRI) measurements including functional MRI (fMRI): A) 1st MRI measurement, B) 2nd MRI measurement, and C) 3rd MRI measurement.

Figure 3 – Schematic diagram of the scan paradigm of four different task-related functional magnetic resonance imaging (fMRI) at visits 2, 3, and 4. All task-related fMRIs identically start with a “baseline” rest (60s, no specific stimulus or task is performed), a “baseline” rating of desire to void and level of pain, a short rest jittered between 7 to 9s in which blood-level-oxygen-dependent (BOLD) activation resulting from motor activity during the previous rating will return to baseline to avoid contamination of the following condition, and conclude with a “last” rest (60s, no specific stimulus or task is performed).

All task-related fMRIs consist of 8 repetitive blocks, each with either 5 (1st and 4th fMRI) or 8 (2nd and 3rd fMRI) conditions.

A) Conditions of the 1st task-related fMRI: 1) automated infusion of 100mL body warm saline, 2) plateau phase (bladder distention after infusion is perceived), 3) rating of desire to void and level of pain, 4) passive withdrawal to empty the bladder completely, and 5) short rest jittered between 7 to 9s. This task-related fMRI starts with an empty bladder and will be performed in patients with non-neurogenic LUTS in visit 2, 3, and 4, while in healthy controls only at visit 3 (2nd MRI measurement).

B and C) Conditions of the 2nd and 3rd task-related fMRI: 1) automated infusion of 100 mL warm saline, 2) plateau phase (bladder distention after infusion is perceived), 3) rating of desire to void and level of pain, 4) short rest jittered between 7 to 9s in which blood-level-oxygen-dependent (BOLD) activation resulting from motor activity during the previous rating will return to baseline to avoid contamination of the following condition, 5) automated withdrawal of 100mL, 6) plateau phase (bladder distention after withdrawal is perceived), 7) rating of desire to void and level of pain, and 8) short rest jittered between 7 to 9s in which blood-level-oxygen-dependent (BOLD) activation resulting from motor activity during the previous rating will return to baseline to avoid contamination of the following condition. The 2nd task-related fMRI (B) starts with a low prefilled bladder volume (100mL) and will be performed only in healthy controls at visit 2 and 3 (1st and 2nd MRI measurement). The 3rd

1
2
3 task-related fMRI (C) starts with a high prefilled bladder volume (persistent desire to void)
4 and will be performed in all subjects (patients with non-neurogenic LUTS and healthy
5 controls) during visit 2 and 3 (1st and 2nd MRI measurement). Additionally, this task-related
6 fMRI will be carried out in patients with non-neurogenic LUTS at visit 4 (3rd MRI
7 measurement).
8
9

10 D) Conditions of the 4th task-related fMRI task: 1) automated infusion of 100mL cold (4-8°C)
11 saline, 2) plateau phase (bladder distention after infusion is perceived), 3) rating of desire to
12 void and level of pain, 4) passive withdrawal to empty the bladder completely, and 5) short
13 rest jittered between 7 to 9s. This task-related fMRI starts with an empty bladder and will be
14 performed in all subjects (patient
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 – Inclusion and exclusion criteria for all subjects.

Groups	Inclusion criteria	Exclusion criteria
All subjects	<ul style="list-style-type: none"> ▪ Right-handed ▪ Gender (female and male) ▪ Age limits: 18-55 years ▪ MR suitability ▪ Written informed consent 	<ul style="list-style-type: none"> ▪ Pregnancy or breast feeding ▪ Any craniocerebral injury or surgery ▪ Any permanent ferromagnetic implant ▪ Any previous surgery of LUT / genitalia ▪ Any anatomical anomaly of LUT / genitalia ▪ Any LUT malignancy ▪ PVR > 150mL ▪ UTI
Healthy controls	<ul style="list-style-type: none"> ▪ Unimpaired LUT function ▪ No LUTS (3-day bladder diary) <ul style="list-style-type: none"> ▪ No episode of urinary urgency / week ▪ Urinary frequency < 8 / 24h 	<ul style="list-style-type: none"> ▪ Impaired LUT function ▪ Any LUTS (3-day bladder diary) <ul style="list-style-type: none"> ▪ Any number of episodes of urinary urgency / week ▪ Urinary frequency > 8 / 24h
Patients with non-neurogenic LUTS	<ul style="list-style-type: none"> ▪ LUTS > 6 months (3-day bladder diary) <ul style="list-style-type: none"> ▪ ≥ 2 episodes of urinary urgency / week ▪ Urinary frequency > 8 / 24h 	<ul style="list-style-type: none"> ▪ Any neurological, psychological, metabolic, or cardiovascular disease ▪ Any concomitant treatment for the LUT (e.g. neuromodulation) ▪ SUI ▪ Indwelling catheters or necessity to perform ISC

MR = Magnet resonance, LUT = Lower urinary tract, LUTS = Lower urinary tract symptoms,

PVR = Post void residual, UTI = Urinary tract infection, SUI = Stress urinary incontinence,

ISC = Intermittent self-catheterization

1
2
3 **Protocol for a prospective neuro-imaging study investigating the supraspinal control**
4 **of lower urinary tract function in healthy controls and patients with non-neurogenic**
5 **lower urinary tract symptoms**
6
7

8
9 Matthias Walter¹, Lars Michels², Spyros Kollias², Philip E. van Kerrebroeck³, Thomas M.
10 Kessler¹, Ulrich Mehnert¹
11

12
13 ¹ Neuro-Urology, Spinal Cord Injury Centre & Research, University of Zürich, Balgrist
14 University Hospital, Zürich, Switzerland

15
16 ² Institute of Neuro-Radiology, University of Zürich, University Hospital Zürich, Zürich,
17 Switzerland
18

19
20 ³ Department of Urology, University Hospital Maastricht, Maastricht, The Netherlands
21

22
23 Corresponding author: Ulrich Mehnert, M.D.
24 Neuro-Urology
25 Spinal Cord Injury Center & Research
26 University of Zürich
27
28

29
30 Balgrist University Hospital

31 Forchstrasse 340

32 8008 Zürich

33 Switzerland
34

35
36 Phone: +41 44 386 37 21

37
38 Fax: +41 44 386 37 31

39
40 Email: ulrich.mehnert@paralab.balgrist.ch
41

42
43 Keywords: Neuro-Urology, bladder disorders, urinary incontinence, neuroradiology
44

45
46 Word count (excluding title page, abstract, references, figures and tables): 2826
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Lower urinary tract symptoms (LUTS) are highly prevalent, cause an enormous economic burden on health care systems, and significantly impair quality of life (QoL) of affected patients. The dependence of the lower urinary tract (LUT) on complex central neuronal circuits makes it unique in comparison to other visceral functions, such as the gastrointestinal tract, but also more vulnerable to neurological diseases.

Methods & analysis: This is a prospective neuro-imaging study investigating the supraspinal control of LUT function in healthy controls and patients with non-neurogenic LUTS.

The clinical assessment will include medical history, neuro-urological examination, bladder diary, urine analysis, urodynamic investigations, as well as standardized questionnaires regarding LUTS and QoL.

The acquisition of neuro-imaging data will include structural assessments (T1-weighted imaging and diffusion tensor imaging (DTI)) as well as functional investigations using blood-oxygen-level-dependent (BOLD) sensitive functional magnetic resonance imaging (fMRI) in a 3 Tesla MR scanner. The fMRI will be performed during four different bladder tasks using an automated MR-compatible and MR-synchronised pump system. The first three task-related fMRIs will consist of automated, repetitive filling of 100mL warm (37°C) saline starting with (1) an empty bladder, (2) a low prefilled bladder volume (100mL), and (3) a high prefilled bladder volume (persistent desire to void). The 4th task-related fMRI will comprise of automated, repetitive filling of 100mL cold (4-8°C) saline starting with an empty bladder.

Ethics & dissemination:

The local ethics committee approved this study (KEK-ZH-Nr. 2011-0346). The findings of the study will be published in peer-reviewed journals and presented at national and international scientific meetings.

Trial registration:

This study has been registered at [clinicaltrials.gov](http://www.clinicaltrials.gov) (<http://www.clinicaltrials.gov/ct2/show/NCT01768910>).

ARTICLE SUMMARY

Study focus

- To demonstrate correlations between alterations in brain structural and functional connectivity in relation to LUT control and LUTS, i.e. urgency with or without urgency urinary incontinence, and urinary frequency.
- To compare clinical correlates of treatment efficacy in patients with non-neurogenic LUTS with the associated changes in brain activity and connectivity.

Key messages

- Although recent neuro-imaging studies in humans and neuro-physiological animal studies have contributed to establish concepts of spinal and supraspinal LUT control, the exact pathophysiological mechanisms involved in human LUTS are still largely unknown.
- A multimodal neuro-imaging approach has considerable potential to broaden our knowledge of the supraspinal LUT control, and helps to adapt current concepts of LUT control.

Strengths and limitations of this study

- This will be the first study to identify brain networks of supraspinal LUT control in healthy subjects and abnormalities within such brain networks in patients with non-neurogenic LUTS using structural and functional MRI techniques in correlation with clinical measurements.
- Investigation of test-retest reliability which has not yet been performed for neuroimaging of LUT tasks. However, this is important especially in regard to interpretation of treatment effects.

INTRODUCTION

Lower urinary tract symptoms (LUTS) are highly prevalent, i.e. about 11% in the worldwide population in 2008, and forecasted to increase up to 20% until 2018.^{1 2} Moreover, LUTS cause an enormous economic burden on each health care system,^{3 4} i.e. comparable to diabetes mellitus,⁵ and significantly impair the quality of life (QoL) of affected patients.^{6 7}

For a proper functioning, lower urinary tract (LUT) structures, i.e. bladder, bladder neck, urethra, and urethral sphincter, rely on intact neuronal innervations that are under control of a complex supraspinal network.⁸⁻¹⁰ The dependence of the LUT on such complex central neuronal circuits makes it unique in comparison to other visceral functions, e.g. gastrointestinal tract, but also more vulnerable to neurological diseases.¹⁰

Recent neuro-imaging studies have shown that patients with neurological disorders such as Parkinson's disease (PD)¹¹⁻¹³ and spinal cord injury (SCI)¹⁴ demonstrate different supraspinal activity patterns compared to healthy controls in response to LUT stimulation tasks, which might represent a neural correlate to their LUTS.

Although there are several concepts regarding the human LUT function and neuronal control in normal and pathological conditions, the exact pathophysiological mechanisms involved remain largely unknown.⁹

Despite the popularity of resting-state functional magnetic resonance imaging (RS-fMRI)¹⁵⁻²⁰ and diffusion tensor imaging (DTI)²¹ in other fields in neuroscience, these techniques have not been applied in the context of supraspinal LUT control. There are only two DTI studies published in regard to LUT control in general: (1) a case report by Theadin et al.²² studying spinal cord infarctions and clinical symptoms and (2) a prospective study by van der Jagt et al.²³ investigating architectural configuration and microstructural properties of the sacral plexus.

As cortical and sub-cortical (e.g. brainstem) brain regions are crucial for voluntary LUT control^{10 24 25}, investigation of the supraspinal regions with high-resolution imaging techniques, i.e. fMRI, can significantly contribute to increase our understanding on the effects of supraspinal lesions and alterations related to LUTS.^{10 26}

In this study, we are aiming to identify supraspinal areas associated with LUT control in healthy subjects and in patients with non-neurogenic LUTS. Task-related blood-oxygen-level-dependent (BOLD) and RS-fMRI will be applied as well as structural MRI (T1-weighted MRI and DTI). Hence, we will examine if bladder processing is already altered on the structural level, and on baseline (RS-fMRI) functional connectivity. For example, the multiple repetition of the RS-fMRI will help to understand whether manipulation of sensory perception (induced by infusion and withdrawal) will alter the default mode network²⁰ of the brain. Furthermore, we can examine volumetric parameters (e.g. gray matter concentration) by voxel-based morphometry (VBM)²⁷, structural integrity and connectivity of white matter tracts (DTI) as well as functional connectivity (FC).

This unique and detailed multimodal imaging protocol should pinpoint to structural and functional processing units involved during supraspinal LUT control and should identify all dysfunctional neuronal components in patients with disturbed LUT control.

Importantly, we will investigate the reliability²⁸ of BOLD signals in task-related fMRI and RS-fMRI in healthy subjects and patients with non-neurogenic LUTS. The test-retest validation, i.e. the intra-class correlation coefficient (ICC) for absolute or consistent agreement of subject activations from visit to visit, has not been evaluated in regard to the supraspinal LUT control yet.

METHODS AND ANALYSIS

Study design

This prospective research study will be conducted at the University of Zürich, Zürich, Switzerland.

Study population & recruitment

According to the inclusion and exclusion criteria (Table 1), we will investigate patients with non-neurogenic LUTS and healthy controls with an unimpaired LUT function. Subjects of both groups will be matched according to age and gender.

Patients with non-neurogenic LUTS will be recruited from our own department (Neuro-Urology, Balgrist University Hospital Zürich) and through our partners at the University Hospital Zürich and the Triemli Hospital Zürich. Eligible patients with non-neurogenic LUTS and healthy controls will be invited to a first visit (screening) during which detailed information about the study, in particular the aims, methods, possible risks, and side effects, will be given. After obtaining written informed consent, the following data will be collected: medical history, a 3-day bladder diary, urine sample to exclude urinary tract infection (UTI) and pregnancy in female subjects, urodynamic parameters, and post void residual measured by ultrasound as well as standardized questionnaires regarding LUTS and QoL. The validated German versions of these questionnaires will be used with permission of the International consultation on incontinence modular questionnaire [(ICIQ), Bristol Urological Institute, Southmead Hospital Bristol, UK], and will address the LUTS (ICIQ-LUTS) in both females (ICIQ-FLUTS) and males (ICIQ-MLUTS) whereas the ICIQ-LUTSQoL will display the QoL in regard to LUTS.

Determination of sample size

A power analysis was conducted using G*Power (www.gpower.hhu.de). In order to have sufficient power (0.80) to detect a large effect size (0.80) between healthy subjects and

1
2
3 patients with non-neurogenic LUTS (significance level 0.05), at least 21 participants per
4 group need to be recruited. To demonstrate post-treatment effects in patients with non-
5 neurogenic LUTS compared to their baseline using the same power, effect size and
6 significance level, at least 12 participants for each treatment option are necessary. These
7 sample sizes are in line with earlier studies^{22 23} including our own^{14 29}, which provided
8 statistical evidence using small collectives, i.e. between 12 and 21 subjects.
9
10
11
12

13 Study location

- 14 ▪ Neuro-Urology, Spinal Cord Injury Centre & Research, University of Zürich, Balgrist
15 University Hospital, Zürich, Switzerland
- 16 ▪ MR-Centre, University Hospital Zürich, Zürich, Switzerland

17 Partners

- 18 ▪ NeuroRadiology Clinic, University Hospital Zürich, Zürich, Switzerland
- 19 ▪ Departments of Urology and Gynaecology, University Hospital Zürich, Zürich,
20 Switzerland
- 21 ▪ Department of Urology and Gynaecology, Triemli Hospital, Zürich, Switzerland

22 Investigations

23 Following screening and study inclusion, all subjects will be scheduled for the 2nd and 3rd visit
24 (1st and 2nd MRI measurement) at the MR-Centre. Patients with non-neurogenic LUTS will
25 return for a 4th visit (3rd MRI measurement), either after receiving treatment for LUTS or
26 without treatment acting as a direct control group within the patient cohort (Figure 1).
27

28 All MR measurements (Figure 2) will be performed using a Philips Ingenia 3 Tesla MR
29 scanner (Philips Medical Systems, Best, The Netherlands) with a 16-channel head coil.
30 During the 2nd visit, we will acquire the following neuro-imaging data. Structural
31 measurements will contain T1-weighted MRI and DTI. The functional measurements will
32 comprise of RS-fMRI and task-related fMRI. Four different RS-fMRI will be applied, i.e. (1) at
33 baseline with an empty bladder, (2) with an empty bladder plus transurethral catheter, (3)
34 with a low prefilled bladder (100mL saline, body warm) prior to task-related fMRI, and (4)
35 after a task-related fMRI, to understand whether manipulation of sensory perception (induced
36 by catheter or prefilling) will alter the default mode network.²⁰ The task-related fMRI will be
37 acquired during four different bladder tasks (Figure 3). In order to precisely fill and drain the
38 bladder (i.e. specific volume and duration of time), we designed an automated MR-
39 compatible and MR-synchronised pump system. In the first three task-related fMRI, we will
40 examine the effect of visceral bladder sensation by automated, repetitive filling with 100mL
41 body warm saline starting with (1) an empty bladder, (2) a low prefilled bladder, and (3) a
42 high prefilled bladder (persistent desire to void). The 4th task-related fMRI will consist of
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 automated, repetitive filling of 100mL cold (4-8°C) saline starting with an empty bladder to
4 investigate the neural correlates of cold bladder sensation (Figure 3). Subjects will rate their
5 desire to void and their level of pain using a displayed visual analogue scale and an fMRI-
6 compatible handheld response system.³⁰

7
8
9 During the 2nd MRI measurement (3rd visit, 1 to 4 weeks later), we will utilise a selection of
10 MRI measurements for the purpose of reliability analysis²⁸, i.e. RS-fMRI (baseline with an
11 empty bladder plus transurethral catheter), and task-related fMRI to compare within and
12 between groups.

13
14 The 3rd MRI measurement will be identical to the 1st MRI measurement to evaluate post
15 versus pre-treatment effects in patients with non-neurogenic LUTS. The time from the start of
16 treatment to the 4th visit, i.e. 5 to 7 weeks (Figure 1), is necessary to let clinical improvements
17 develop.^{31 32}

21 22 23 Safety

24 The staff involved in this study will be instructed and trained according to the safety
25 regulations of the MR-Centre of the University Hospital Zürich. All subjects will be asked to
26 remove any ferromagnetic items, e.g. bra, earrings, chains, rings, and piercings prior to
27 entering the scanner room. All subjects will be provided with standardised clinical scrubs
28 instead of wearing their own clothes. Before every MR measurement (visit 2, 3 and 4), urine
29 samples will be analysed from every subject in order to exclude UTI or pregnancy. In case of
30 pregnancy, the subject will be excluded from the study and referred to a gynaecologist. In
31 case of UTI, the subject will not undergo the experiment, but will receive immediate antibiotic
32 treatment if the UTI is symptomatic or treatment depending on further microbiological urine
33 analysis in the absence of UTI symptoms. The subject can be reassigned to the study, if the
34 microbiological urine analysis shows no evidence of an UTI or the UTI has been successfully
35 treated.

36
37 In the situation of an adverse event (AE) or a severe adverse event (SAE), as defined by the
38 international conference on harmonisation (ICH) good clinical practice (GCP) guidelines
39 (E6)³³ and international organization for standardization (ISO, 14155)³⁴, appropriate actions
40 will be executed and the according body (principle investigator, ethics committee) will be
41 informed. All AEs and SAEs will be followed as long as medically indicated.

42 43 44 Study outcome measures

45 46 Primary

47 (A) BOLD signal intensity changes in a priori supraspinal regions of interest (ROI), e.g.
48 pons, insula, anterior cingulate cortex, thalamus, hypothalamus, supplementary motor
49 area, and prefrontal cortex, during task-related fMRI in relation to the specific
50

condition, i.e. infusion or to a contrast, i.e. low versus full bladder volume, during two (healthy controls) or three (patients with non-neurogenic LUTS) visits.

The precise selection of ROIs will be based on the coordinates of the peak activations during task-related fMRI, i.e. taken from the MNI space.

(B) Reliability of BOLD signal changes during RS-fMRI and task-related fMRI across visits (e.g. 2nd and 3rd visit) in healthy subjects and patients with non-neurogenic LUTS.

(C) BOLD signal changes in supraspinal ROIs during task-related fMRI in patients with non-neurogenic LUTS before and after treatment to quantify the link between BOLD signal changes and treatment efficacy.

Secondary

(A) Structural differences, i.e. between healthy subjects and patients with non-neurogenic LUTS, and changes, i.e. post vs pre-treatment state, of gray matter concentration using VBM.

(B) Structural (SC) and functional connectivity (FC) between supraspinal ROIs, e.g. insula, cingulate, and prefrontal cortices, and to identify specific alterations with DTI³⁵, i.e. whole-brain fractional anisotropy (FA) and mean diffusivity (MD) comparison between healthy subjects and patients with non-neurogenic LUTS (incl. post vs pre-treatment changes) as well as probabilistic tractography between ROIs (white matter fibre structure).

(C) Differences of BOLD signals during RS-fMRI between healthy subjects and patients with non-neurogenic LUTS (incl. post vs pre-treatment changes), i.e. intra- and interhemispheric connectivity³⁶ whether these signals already differ at baseline, are influenced by the presence of a catheter, by prefilling and/or by task-related fMRI.

(D) Clinical scores (e.g. bladder volume, urodynamic parameters, and level of desire to void during fMRI) will be correlated to BOLD signal changes as well as to structural markers (e.g. grey matter volume or number of white matter tracts between ROIs) using regression analyses.

Data analysis

Clinical data, e.g. urodynamic parameters, 3-day bladder diary outcome, and questionnaires scores, will be statistically analysed and compared between groups using IBM's Statistical Package for the Social Sciences (SPSS) version 19.0 or newer (Armonk, New York, U.S.) and will be presented with means and standard deviations or with medians and interquartile ranges as appropriate.

1
2
3 The neuro-imaging data will be analysed using statistical parametric mapping (SPM) version
4 12 (Wellcome Department of Imaging Neuroscience, University College London, UK).
5 Preprocessing of functional data from each task-related fMRI will be done for each
6 participant individually. The images will be realigned to the first scan, unwarped to control for
7 movement- and susceptibility-induced image distortions³⁷, spatially coregistered to the T1-
8 weighted image, and normalized to the Montreal Neurologic Institute (MNI) anatomical
9 standard space. At last, the functional data will be smoothed spatially with an isotropic
10 Gaussian kernel. Thereafter, first-level analysis using the general linear model (GLM) will
11 performed to create contrasts of interest, e.g. low vs full bladder or infusion vs withdrawal.³⁸
12 The six movement parameters will be modeled as additional regressors to control for
13 potential head motion.
14
15 Second-level factorial design will include at least (1) one-sample t-tests to compute a mean
16 for each group, (2) two-sample t-tests to compare healthy subjects and patients with non-
17 neurogenic LUTS and (3) paired t-tests to evaluate post- vs. pre-treatment effects in patients
18 with non-neurogenic LUTS. The ICC for task-related and RS-fMRI reliability will be analyzed
19 using the SPM-compatible ICC toolbox
20 ([http://www.kcl.ac.uk/iop/depts/neuroimaging/research/imaginganalysis/Software/ICC-
21 Toolbox.aspx](http://www.kcl.ac.uk/iop/depts/neuroimaging/research/imaginganalysis/Software/ICC-Toolbox.aspx)).
22
23 Association of individual (clinical) variables with BOLD signal changes will be assessed by
24 whole-brain and ROIs-based correlation analyses (correlation coefficients will be reported).
25
26 DTI data will be analysed using TBSS (<http://fsl.fmrib.ox.ac.uk/fsl/fsl4.0/tbss/index>) and
27 BrainVoyager (<http://www.brainvoyager.com/downloads/downloads.html>) with the following
28 established DTI analyses: Whole-brain fractional anisotropy (FA) and mean diffusivity (MD)
29 comparison between groups as well as probabilistic tractography between ROIs. Seed and
30 target regions, i.e. ROIs will be defined (1) a priori using anatomic coordinates, e.g. from the
31 SPM toolbox WFU_PickAtlas (<http://fmri.wfubmc.edu/software/PickAtlas>) and (2) from peak
32 activations acquired from task-related fMRI and RS-fMRI on the standard MNI space.
33
34 Volumetric changes in gray and white matter will be analyzed using voxel-based
35 morphometry (VBM), e.g. the VBM toolbox (<http://dbm.neuro.uni-jena.de/vbm>) in SPM.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ETHICS AND DISSEMINATION

This cohort study will be performed in accordance to the World Medical Association Declaration of Helsinki³⁹ and the guidelines of the Swiss Academy of Medical Sciences.⁴⁰

This study has been approved by the local ethics committee (Kantonale Ethikkommission Zürich, KEK-ZH-Nr. 2011-0346). Furthermore, handling of all personal data will strictly comply with the federal law of data protection in Switzerland.⁴¹

This study has been registered at [clinicaltrials.gov](http://www.clinicaltrials.gov) (<http://www.clinicaltrials.gov/ct2/show/NCT01768910>).

DISCUSSION

This study will investigate supraspinal LUT control in healthy subjects and patients with non-neurogenic LUTS using a multimodal imaging protocol, i.e. structural (T1-weighted and DTI) and fMRI (RS-fMRI and task-related fMRI), to examine hemodynamic responses to LUT stimulation. From the acquired neuro-imaging data, structural (SC) and functional connectivity (FC), and structural integrity evaluation of white matter tracts and gray matter concentration (VBM) will be analysed to identify specific alterations of the supraspinal LUT control. In addition, effects on the supraspinal LUT control after treatment for LUTS (e.g. antimuscarinergics or botulinum toxin) will be investigated. It is expected that this study will provide new insights into the supraspinal neuronal mechanisms and networks responsible for LUT control. The findings will help to verify, amend, or adjust neuronal circuitry models established from findings in healthy subjects, now in the context of patients with non-neurogenic LUTS. Particularly, the use of newer imaging and evaluation techniques has the potential to serve as quantifiable outcome measures for therapy success and provide evidence for non-responders of LUTS treatment.

Author affiliations

1 Neuro-Urology, Spinal Cord Injury Centre & Research, University of Zürich, Balgrist University Hospital, Zürich, Switzerland

2 Institute of Neuro-Radiology, University of Zürich, University Hospital Zürich, Zürich, Switzerland

3 Department of Urology, University Hospital Maastricht, Maastricht, The Netherlands

Acknowledgements

We would like to acknowledge the Swiss National Science Foundation, SwissLife Jubiläumsstiftung, and Swiss Continence Foundation for financial support. Furthermore, we would like to thank our partners contributing to this study: Departments of Urology and Gynaecology of the University Hospital Zürich and Departments of Urology and Gynaecology, Triemli Hospital, Zürich, Switzerland.

We thank Behnaz Jarrahi for granting figure contents.

Contributors

All authors participated in creating the study design.

MW and UM drafted the manuscript.

LM, SK, PEVK and TMK critically reviewed the manuscript.

UM, SK and TMK obtained the funding of this study.

All the authors read and approved the final manuscript.

Funding

Swiss National Science Foundation (grant number: 135774)

SwissLife Jubiläumsstiftung

Swiss Continence Foundation

Competing interests

The authors declare that they have no competing interests.

REFERENCES

1. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. *BJU Int* 2011;108(7):1132-8.
2. Irwin DE, Milsom I, Hunzkaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. *Eur Urol* 2006;50(6):1306-14; discussion 14-5.
3. Ganz ML, Smalarz AM, Krupski TL, Anger JT, Hu JC, Wittrup-Jensen KU, et al. Economic costs of overactive bladder in the United States. *Urology* 2010;75(3):526-32, 32 e1-18.
4. Klotz T, Bruggenjürgen B, Burkart M, Resch A. The economic costs of overactive bladder in Germany. *Eur Urol* 2007;51(6):1654-62; discussion 62-3.
5. Hampel C, Gillitzer R, Pahernik S, Hohenfellner M, Thuroff JW. [Epidemiology and etiology of overactive bladder]. *Urologe A* 2003;42(6):776-86.
6. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. *BJU Int* 2008;101(11):1388-95.
7. Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. *BJU Int* 2006;97(1):96-100.
8. Blok BF. Brain control of the lower urinary tract. *Scand J Urol Nephrol Suppl* 2002(210):11-5.
9. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. *Nat Rev Neurosci* 2008;9(6):453-66.
10. Fowler CJ, Griffiths DJ. A decade of functional brain imaging applied to bladder control. *NeuroUrol Urodyn* 2010;29(1):49-55.
11. Herzog J, Weiss PH, Assmus A, Wefer B, Seif C, Braun PM, et al. Subthalamic stimulation modulates cortical control of urinary bladder in Parkinson's disease. *Brain* 2006;129(Pt 12):3366-75.
12. Herzog J, Weiss PH, Assmus A, Wefer B, Seif C, Braun PM, et al. Improved sensory gating of urinary bladder afferents in Parkinson's disease following subthalamic stimulation. *Brain* 2008;131(Pt 1):132-45.
13. Kitta T, Kakizaki H, Furuno T, Moriya K, Tanaka H, Shiga T, et al. Brain activation during detrusor overactivity in patients with Parkinson's disease: a positron emission tomography study. *J Urol* 2006;175(3 Pt 1):994-8.
14. Mehnert U, Michels L, Zemleni MZ, Schurch B, Kollias S. The supraspinal neural correlate of bladder cold sensation--an fMRI study. *Hum Brain Mapp* 2011;32(6):835-45.
15. Biswal BB, Van Kylen J, Hyde JS. Simultaneous assessment of flow and BOLD signals in resting-state functional connectivity maps. *NMR Biomed* 1997;10(4-5):165-70.
16. Cauda F, Costa T, Torta DM, Sacco K, D'Agata F, Duca S, et al. Meta-analytic clustering of the insular cortex: characterizing the meta-analytic connectivity of the insula when involved in active tasks. *Neuroimage* 2012;62(1):343-55.
17. Greicius MD, Supekar K, Menon V, Dougherty RF. Resting-state functional connectivity reflects structural connectivity in the default mode network. *Cereb Cortex* 2009;19(1):72-8.
18. Gusnard DA, Akbudak E, Shulman GL, Raichle ME. Medial prefrontal cortex and self-referential mental activity: relation to a default mode of brain function. *Proc Natl Acad Sci U S A* 2001;98(7):4259-64.
19. Gusnard DA, Raichle ME. Searching for a baseline: functional imaging and the resting human brain. *Nat Rev Neurosci* 2001;2(10):685-94.

- 1
- 2
- 3 20. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default
- 4 mode of brain function. *Proc Natl Acad Sci U S A* 2001;98(2):676-82.
- 5 21. Basser PJ, Mattiello J, LeBihan D. MR diffusion tensor spectroscopy and imaging.
- 6 *Biophys J* 1994;66(1):259-67.
- 7 22. Theaudin M, Saliou G, Denier C, Adams D, Ducreux D. A correlation between fractional
- 8 anisotropy variations and clinical recovery in spinal cord infarctions. *J Neuroimaging*
- 9 2013;23(2):256-8.
- 10 23. van der Jagt PK, Dik P, Froeling M, Kwee TC, Nievelstein RA, ten Haken B, et al.
- 11 Architectural configuration and microstructural properties of the sacral plexus: a
- 12 diffusion tensor MRI and fiber tractography study. *Neuroimage* 2012;62(3):1792-9.
- 13 24. Andrew J, Nathan PW. Lesions on the Anterior Frontal Lobes and Disturbances of
- 14 Micturition and Defaecation. *Brain* 1964;87:233-62.
- 15 25. Holstege G. Micturition and the soul. *J Comp Neurol* 2005;493(1):15-20.
- 16 26. de Groat WC. A neurologic basis for the overactive bladder. *Urology* 1997;50(6A
- 17 Suppl):36-52; discussion 53-6.
- 18 27. Ashburner J, Friston KJ. Voxel-based morphometry--the methods. *Neuroimage*
- 19 2000;11(6 Pt 1):805-21.
- 20 28. Caceres A, Hall DL, Zelaya FO, Williams SC, Mehta MA. Measuring fMRI reliability with
- 21 the intra-class correlation coefficient. *Neuroimage* 2009;45(3):758-68.
- 22 29. Michels L, Mehnert U, Boy S, Schurch B, Kollias S. The somatosensory representation of
- 23 the human clitoris: an fMRI study. *Neuroimage* 2010;49(1):177-84.
- 24 30. Jarrahi B, Wanek J, Mehnert U, Kollias S. An fMRI-compatible multi-configurable
- 25 handheld response system using an intensity-modulated fiber-optic sensor. *Conf Proc*
- 26 *IEEE Eng Med Biol Soc* 2013;2013:6349-52.
- 27 31. Agency for Healthcare Research and Quality. Treatment of Overactive Bladder in
- 28 Women, 2009.
- 29 32. Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis
- 30 and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline.
- 31 *J Urol* 2012;188(6 Suppl):2455-63.
- 32 33. International conference on harmonisation. Good clinical practice guideline, 1996.
- 33 34. International organization for standardization. ISO 14155, 2011.
- 34 35. Kucyi A, Moayed M, Weissman-Fogel I, Hodaie M, Davis KD. Hemispheric asymmetry in
- 35 white matter connectivity of the temporoparietal junction with the insula and prefrontal
- 36 cortex. *PLoS One* 2012;7(4):e35589.
- 37 36. Maldjian JA, Davenport EM, Whitlow CT. Graph Theoretical Analysis of Resting-State
- 38 MEG data: Identifying Interhemispheric Connectivity and the Default Mode.
- 39 *Neuroimage* 2014.
- 40 37. Andersson JL, Hutton C, Ashburner J, Turner R, Friston K. Modeling geometric
- 41 deformations in EPI time series. *Neuroimage* 2001;13(5):903-19.
- 42 38. Friston KJ, Holmes AP, Poline JB, Grasby PJ, Williams SC, Frackowiak RS, et al.
- 43 Analysis of fMRI time-series revisited. *Neuroimage* 1995;2(1):45-53.
- 44 39. World Medical Association. Declaration of Helsinki - Ethical principles for medical
- 45 research involving human subjects, 1964.
- 46 40. Swiss Academy of Medical Sciences. Guideline - Concerning scientific research involving
- 47 human beings, 2009.
- 48 41. The Federal Authorities of the Swiss Confederation. Bundesgesetz über den
- 49 Datenschutz (DSG) vom 19. Juni 1992, Stand. 01.01.2011, 1992.
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60




Figure 1 – Timetable and characteristics of all four visits.
 PVR = Post void residual, LUTS = Lower urinary tract symptoms, QoL = Quality of life

169x83mm (300 x 300 DPI)

review only





Figure 2 – Schematic protocol of operational sequences of magnetic resonance imaging (MRI) measurements including functional MRI (fMRI): A) 1st MRI measurement, B) 2nd MRI measurement, and C) 3rd MRI measurement.
171x95mm (300 x 300 DPI)



45 Figure 3 – Schematic diagram of the scan paradigm of four different task-related functional magnetic
 46 resonance imaging (fMRI) at visits 2, 3, and 4. All task-related fMRIs identically start with a “baseline” rest
 47 (60s, no specific stimulus or task is performed), a “baseline” rating of desire to void and level of pain, a
 48 short rest jittered between 7 to 9s in which blood-level-oxygen-dependent (BOLD) activation resulting from
 49 motor activity during the previous rating will return to baseline to avoid contamination of the following
 50 condition, and conclude with a “last” rest (60s, no specific stimulus or task is performed).
 51 All task-related fMRIs consist of 8 repetitive blocks, each with either 5 (1st and 4th fMRI) or 8 (2nd and 3rd
 52 fMRI) conditions.

53 A) Conditions of the 1st task-related fMRI: 1) automated infusion of 100mL body warm saline, 2) plateau
 54 phase (bladder distention after infusion is perceived), 3) rating of desire to void and level of pain, 4) passive
 55 withdrawal to empty the bladder completely, and 5) short rest jittered between 7 to 9s. This task-related
 56 fMRI starts with an empty bladder and will be performed in patients with non-neurogenic LUTS in visit 2, 3,
 57 and 4, while in healthy controls only at visit 3 (2nd MRI measurement).

58 B and C) Conditions of the 2nd and 3rd task-related fMRI: 1) automated infusion of 100 mL warm saline, 2)

1
2
3 plateau phase (bladder distention after infusion is perceived), 3) rating of desire to void and level of pain, 4)
4 short rest jittered between 7 to 9s in which blood-level-oxygen-dependent (BOLD) activation resulting from
5 motor activity during the previous rating will return to baseline to avoid contamination of the following
6 condition, 5) automated withdrawal of 100mL, 6) plateau phase (bladder distention after withdrawal is
7 perceived), 7) rating of desire to void and level of pain, and 8) short rest jittered between 7 to 9s in which
8 blood-level-oxygen-dependent (BOLD) activation resulting from motor activity during the previous rating will
9 return to baseline to avoid contamination of the following condition. The 2nd task-related fMRI (B) starts
10 with a low prefilled bladder volume (100mL) and will be performed only in healthy controls at visit 2 and 3
11 (1st and 2nd MRI measurement). The 3rd task-related fMRI (C) starts with a high prefilled bladder volume
12 (persistent desire to void) and will be performed in all subjects (patients with non-neurogenic LUTS and
13 healthy controls) during visit 2 and 3 (1st and 2nd MRI measurement). Additionally, this task-related fMRI
14 will be carried out in patients with non-neurogenic LUTS at visit 4 (3rd MRI measurement).

15 D) Conditions of the 4th task-related fMRI task: 1) automated infusion of 100mL cold (4-8°C) saline, 2)
16 plateau phase (bladder distention after infusion is perceived), 3) rating of desire to void and level of pain, 4)
17 passive withdrawal to empty the bladder completely, and 5) short rest jittered between 7 to 9s. This task-
18 related fMRI starts with an empty bladder and will be performed in all subjects (patient
19 167x192mm (300 x 300 DPI)
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60